Corcept (CORT) executive sells 25K shares after exercising options
Corcept Therapeutics executive Sean Maduck exercised options for 25,000 shares at $8.27 each and subsequently sold all 25,000 shares in open-market transactions at an average price between $87 and $89 per share. These transactions were made under a Rule 10b5-1 trading plan established in December 2025. Following these sales, Maduck directly holds 34,755 common shares and 116,986 stock options, with additional indirect holdings through various trusts and LLCs.
Corcept Therapeutics stock hits 52-week high at 91.1 USD
Corcept Therapeutics (CORT) stock recently hit a new 52-week high of $91.10, marking significant appreciation over the past year and year-to-date. This surge has increased the company's market capitalization to $9.68 billion, although InvestingPro analysis suggests the stock is currently overvalued and in overbought territory. Recent developments include the resubmission of its New Drug Application for relacorilant for Cushing’s syndrome and promising Phase 3 trial data for Lifyorli in ovarian cancer treatment.
Does Corcept’s Exit From Russell Defensive Indexes Reframe Its Risk Profile And Investor Base (CORT)?
Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indexes in late June 2026, which may influence index-tracking investors and shift demand for its stock. This move highlights how sentiment and ownership patterns can change as Corcept pursues diversification through its relacorilant NDA for Cushing’s syndrome. While the index removal doesn't alter core business drivers, it coincides with the company's effort to reduce single-product dependence and achieve significant revenue and earnings growth projections by 2029.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak June US jobs report, healthcare stocks are gaining attention as investors rotate out of semiconductor and AI sectors. The report highlighted job growth primarily in healthcare, prompting a focus on resilient companies in this market. This article identifies three healthcare stocks—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that appear well-positioned for the current economic climate, offering insights into their operations, market positions, and growth prospects.
CORT - Corcept Therapeutics Inc Options
This article provides a detailed financial overview of Corcept Therapeutics Inc. (CORT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider and institutional ownership, profitability margins, and stock performance over different periods.
If You Invested $1,000 in Corcept Therapeutics Inc (CORT)
This article analyzes the historical performance of an investment in Corcept Therapeutics Inc (CORT). It details how a $1,000 investment would have grown over 1, 5, and 10 years, showcasing significant returns. The article also provides a comprehensive overview of Corcept Therapeutics, including its focus on cortisol modulation, key products like Korlym and relacorilant, ongoing clinical trials, and regulatory milestones.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak June US jobs report, investors are shifting focus to the healthcare sector for resilience as other markets become uncertain. This article highlights three healthcare stocks – Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD) – that offer diverse opportunities, from specialized biopharmaceuticals to medical devices and global biopharma. These companies are generating interest due to their potential for growth, strong financials, or critical market positioning amidst the changing economic landscape.
Healthcare Stocks Investors Are Turning To After The Weak US Jobs Report
Following a weak US jobs report in June, investors are shifting focus to healthcare stocks, moving away from semiconductor and AI sectors. This article highlights three healthcare companies—Corcept Therapeutics (CORT), Insulet (PODD), and Gilead Sciences (GILD)—that are well-positioned for resilience amidst economic uncertainties. Each company offers unique strengths, from pipeline advancements and recurring revenue models to strong market presence and dividends, making them attractive in the current investment climate.
Is Corcept Therapeutics (CORT) Undervalued On Its Russell Index Removal?
Corcept Therapeutics (CORT) was removed from the Russell 1000 Defensive and Growth-Defensive Indices, prompting questions about its valuation despite strong recent share price momentum. While a prominent narrative suggests the stock is 1% overvalued at $88 due to expected revenue growth from its CATALYST study, Simply Wall St's DCF model indicates it's slightly undervalued by 1.4% at $89.78. Investors are cautioned to consider risks like patent litigation or regulatory delays.
CORT - Corcept Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Corcept Therapeutics Inc (CORT), including its volatility, key financial ratios, performance metrics, and insider/institutional ownership data. It presents a snapshot of the company's market cap, earnings per share, sales growth, and various valuation multiples as of July 2, 2026. The data also covers short interest, analyst recommendations, and historical price performance over different periods.
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT
This article provides the forward price-to-sales ratio for Corcept Therapeutics Incorporated (NASDAQ: CORT). It primarily consists of metadata and navigation elements from the TradingView platform, where this financial data point is located. The core content is the mention of the company and its forward price-to-sales metric.
Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT
This article focuses on the enterprise value to revenue forward for Corcept Therapeutics Incorporated (NASDAQ: CORT). It presents financial data for the company within the context of the pharmaceuticals industry on TradingView. The page provides a snapshot of CORT's financials and market information.
Corcept sinks after FDA rejects drug to treat hypertension
The article states that Corcept's stock sank after the FDA rejected its drug for hypertension, which was a significant setback for the company. There is no further content provided to elaborate on the details of the rejection or its potential impact.
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index
Corcept Therapeutics Incorporated (NasdaqCM:CORT) has been removed from the Russell 1000 Defensive Index. This news follows a series of recent announcements for the company, including the resubmission of its NDA for a Cushing Syndrome treatment and several insider share sales. Despite the index change, the company's stock has seen significant year-to-date growth.
Corcept gives FDA new relacorilant data in resubmitted application
Corcept Therapeutics has resubmitted its application to the FDA for relacorilant, a treatment for endogenous Cushing's syndrome, including new data analyses requested by the agency. The resubmission provides additional evidence from Phase 3 trials (GRACE and GRADIENT) demonstrating relacorilant's ability to reduce high blood pressure and high blood sugar, common manifestations of the condition. The company anticipates a six-month review period for the resubmitted application.
Why Corcept Therapeutics (CORT) Is Up 6.1% After Resubmitting Its Cushing’s Drug NDA to FDA
Corcept Therapeutics (CORT) saw its shares rise 6.1% after resubmitting its New Drug Application (NDA) for relacorilant, a Cushing’s syndrome drug, to the FDA. The resubmission includes additional clinical data analyses and is expected to have a six-month review period. This development, along with a recent approval for Lifyorli and high revenue guidance, is influencing Corcept's investment narrative, though earnings compression and legal overhangs present continued risks.
Corcept Therapeutics Incorporated. Actuals & Estimates (NASDAQ:CORT)
This article provides an in-depth financial overview of Corcept Therapeutics Incorporated (CORT), including its stock performance, analyst forecasts, historical prices, volatility, market capitalization, and earnings reports. It details past earnings surprises and revenue figures, along with the company's employee count and EBITDA, while also offering guidance on how to invest in CORT stock.
Number of shareholders of Corcept Therapeutics Incorporated. – BX:HTD
This article from TradingView provides a link to financial information and other data for Corcept Therapeutics Incorporated. (BX:HTD). It focuses on the number of shareholders for the company, indicating the available data points such as period, value, change, and change percentage. The page itself serves as a portal to various financial tools and market data provided by ICE Data Services and FactSet.
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Kuehn Law,PLLC is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) regarding potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that the company failed to disclose concerns from the FDA about its clinical development program for relacorilant, making the New Drug Application prone to rejection. Shareholders who purchased CORT prior to October 31, 2024, are encouraged to contact the law firm.
HTD Forecast — Price Target — Prediction for 2027
The article provides forecast and price target information for Corcept Therapeutics Incorporated. (HTD) stock on the Frankfurt Stock Exchange. It includes analyst ratings, future price estimates with maximum and minimum figures, and details on past earnings, revenue, and key financial metrics. The piece also addresses frequently asked questions about the company's stock, such as its ticker, historical prices, earnings calendar, and employee count.
Corcept resubmits NDA for relacorilant in Cushing's syndrome
Corcept Pharmaceuticals has resubmitted its New Drug Application (NDA) for relacorilant, an investigational treatment for Cushing's syndrome, to the FDA. The resubmission follows an earlier complete response letter from the FDA. This marks a step forward in potentially bringing a new treatment option to patients with Cushing's syndrome.
Corcept Therapeutics (CORT) Stock Could Be 9.2% Undervalued After Relacorilant FDA Resubmission
Corcept Therapeutics (CORT) has resubmitted its New Drug Application for relacorilant to the FDA for Cushing’s syndrome, incorporating additional data. The stock is currently trading at $79.91, approximately 9.2% below a narrative fair value of $88, suggesting it might be undervalued. This valuation is based on anticipated revenue growth from relacorilant's potential approvals for Cushing's syndrome and platinum-resistant ovarian cancer, though risks like generic competition for Korlym and approval disappointments could alter this outlook.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant to the FDA for the treatment of Cushing's syndrome, anticipating a six-month review period. This resubmission follows a complete response letter in December 2025 and includes additional data analyses from the GRACE and GRADIENT studies. The company believes relacorilant offers a meaningful and durable improvement for Cushing's syndrome symptoms with fewer side effects than current therapies, and approval would diversify Corcept's revenue beyond its sole-marketed drug, Korlym.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Corcept Therapeutics (CORT) has resubmitted its New Drug Application (NDA) for relacorilant to the FDA as a treatment for Cushing's syndrome, following a previous complete response letter. The resubmission includes additional analyses of data from multiple studies and seeks a six-month review period. The company also recently received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, aiming to diversify its revenue beyond its sole marketed drug, Korlym.
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Corcept Therapeutics Inc (CORT) stock performance, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also presents current stock metrics like market cap and P/E ratio.
How Corcept’s Relacorilant NDA Resubmission Could Reshape CORT’s Single‑Drug Dependence Risk Profile
Corcept Therapeutics has resubmitted its New Drug Application to the FDA for relacorilant to treat Cushing’s syndrome, incorporating additional study analyses. This resubmission is a key near-term catalyst for CORT, aiming to broaden its treatment portfolio beyond Korlym and reduce single-drug dependence, which has been a primary investment risk. The potential approval of relacorilant could also expand the treatable patient pool, especially for hypercortisolism associated with difficult-to-manage type 2 diabetes and resistant hypertension.
Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan
A trust associated with Corcept Therapeutics director James N. Wilson sold 10,000 shares of Common Stock on June 16, 2026, through open-market transactions under a pre-planned Rule 10b5-1 trading plan. The sales occurred at weighted average prices between $82.6948 and $83.5708 per share. Despite the sale, the trust retains over 1.09 million shares, indicating a routine, pre-scheduled transaction rather than a significant divestment.
Corcept (CORT) director’s entities report 20K-share sale and large holdings
Corcept Therapeutics director David L. Mahoney's Black Dog Private Foundation sold 20,000 shares of common stock at a weighted average price of $84.5253 per share. After the sale, the foundation retains 26,147 shares, while the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust holds 1,237,145 shares. This indirect open-market sale is detailed in a Form 4 SEC filing, highlighting the insider transaction.
Corcept Therapeutics(CORT.US) Officer Sells US$3.25 Million in Common Stock
An officer at Corcept Therapeutics (CORT.US) sold common stock worth $3.25 million. This insider transaction indicates a significant sale by a company executive.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant to the FDA for the treatment of Cushing's syndrome, anticipating a six-month review period. This resubmission includes additional analyses requested by the FDA after a previous complete response letter in December 2025. The company aims to reduce its reliance on Korlym, its sole marketed drug for Cushing's syndrome, with relacorilant's potential approval and the recent FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant to the FDA for the treatment of Cushing's syndrome after an initial complete response letter. The resubmission includes additional data analyses and is expected to undergo a six-month review. Corcept believes relacorilant can provide significant symptom improvement without the severe side effects of current therapies, and its approval would reduce the company's reliance on its sole-marketed drug, Korlym.
Corcept Therapeutics Inc (CORT) Institutional Confidence
This article analyzes the institutional confidence in Corcept Therapeutics Inc (CORT), noting its current score of 7.00, placing it 51st in the Pharmaceuticals industry. The institutional shareholding stands at 71.62%, a decrease of 14.25% quarter-over-quarter. It lists key institutional shareholders and their holdings, with James Simons being the largest.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, a selective cortisol modulator, to the FDA for the treatment of Cushing’s syndrome. The resubmission includes additional data analyses requested by the FDA after a complete response letter in December 2025. This move aims to secure approval for relacorilant, which has shown promise in improving Cushing's symptoms with fewer side effects and could reduce Corcept's reliance on its existing drug, Korlym.
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant to the U.S. FDA, seeking approval for its use in treating Cushing’s syndrome. The resubmission includes additional data analyses requested by the FDA, and Corcept anticipates a six-month review period. The company believes relacorilant, an oral selective glucocorticoid receptor antagonist, offers significant improvements for Cushing’s syndrome patients without the severe side effects associated with current treatments.
Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, a treatment for Cushing's syndrome, to the U.S. Food and Drug Administration (FDA). The resubmission includes additional analyses requested by the FDA and is anticipated to undergo a six-month review. Corcept emphasizes that positive data from its GRACE and GRADIENT trials, along with other studies, demonstrate significant and lasting improvements in Cushing's symptoms without some of the severe side effects seen with current therapies.
Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally Justified
Corcept Therapeutics (CORT) has seen a significant 114% year-to-date surge, leading to questions about its valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is fairly valued at $83.61 per share, trading at a 2.2% discount to its current price of $81.75. However, a Price vs. Sales (P/S) ratio analysis indicates it could be undervalued at 11.41x compared to its estimated "Fair Ratio" of 15.74x.
Corcept Therapeutics (CORT) Resubmits NDA for Relacorilant with New Data
Corcept Therapeutics (CORT) has resubmitted its New Drug Application (NDA) for relacorilant, a treatment for Cushing’s syndrome, to the FDA, including additional data analyses after a previous Complete Response Letter. The company, with a strong GF Score and high profitability, has insider selling totaling $17.7 million over the last three months, and its stock has an elevated P/E ratio of 233.57x. Investors are advised to exercise caution due to the high valuation and insider selling activity.
Corcept sends relacorilant back to FDA review for Cushing’s syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, a treatment for Cushing's syndrome, to the FDA. The resubmission includes additional data analyses, as requested by the FDA, and is expected to undergo a six-month review. Corcept is hopeful for approval, citing positive data from clinical trials demonstrating relacorilant's ability to improve Cushing's syndrome symptoms without the severe side effects associated with current treatments.
Corcept resubmits drug application for Cushing’s syndrome treatment
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, a treatment for Cushing’s syndrome, to the U.S. FDA, including additional data analyses requested by the agency. The company anticipates a six-month review period for the resubmission. This follows positive data from multiple trials and recent financial reports showing increased revenue, an updated full-year guidance, and a significant stock price target increase from analysts like H.C. Wainwright.
Corcept Therapeutics (CORT) CFO exercises options, sells 40,000 shares in 10b5-1 trades
Corcept Therapeutics' CFO, Atabak Mokari, exercised stock options for 40,000 shares at $19.26 per share and subsequently sold all 40,000 shares in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices ranging from approximately $79.40 to $82.18 per share. Following these transactions, Mokari directly holds 16,130 common shares, which include unvested restricted stock awards.
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Kuehn Law, a shareholder litigation law firm, is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) for alleged breaches of fiduciary duties by its officers and directors. The investigation stems from a federal securities lawsuit claiming the company failed to disclose FDA concerns regarding its new product candidate, relacorilant, and the material risk of its New Drug Application being rejected. Investors who purchased CORT prior to October 31, 2024, are encouraged to contact Kuehn Law.
[144] CORCEPT THERAPEUTICS INC SEC Filing
This article details a Form 144 SEC filing by Corcept Therapeutics Inc. (CORT) on June 16, 2026, concerning a proposed sale of securities. The filing specifies the class of securities, number of shares, aggregate market value, acquisition details, and confirms the absence of past sales in the last three months. It also includes an important legal disclaimer regarding material adverse information.
Korlym improves results for diabetes patients taking GLP-1 drugs
New analysis from the CATALYST clinical trial indicates that Korlym (mifepristone) can help lower blood sugar and promote weight loss in diabetes patients with high cortisol levels who are also on GLP-1 targeting medications. Corcept Therapeutics presented these findings, which suggest that modulating cortisol can improve metabolic parameters even for those with poorly controlled type 2 diabetes despite powerful GLP-1 therapies. Korlym works by blocking cortisol receptors and has shown better results than placebo in reducing HbA1c, body weight, waist circumference, and BMI.
CORT stock rises 42% in a month: Here's what you should know
The article states that CORT stock has increased by 42% over the past month. It implies that investors should be aware of this significant price movement. However, the provided content is only "MSN," indicating the full article text is missing.
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT
Clearbridge Investments LLC significantly reduced its stake in Corcept Therapeutics (NASDAQ:CORT) by 56.3% in the fourth quarter, holding 507,354 shares valued at $17.66 million. Despite this, Corcept Therapeutics has received an average "Moderate Buy" rating from analysts with an $88.83 target price. The company recently reported a quarterly EPS loss of $0.30, missing estimates, and revenue of $164.9 million, also below expectations, though its stock remains near its 12-month high.
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT
Norges Bank has initiated a new position in Corcept Therapeutics ($CORT) during the fourth quarter, acquiring 695,766 shares valued at approximately $24.2 million, representing 0.66% of the company. This comes despite Corcept Therapeutics reporting weaker-than-expected quarterly results, with an EPS loss of $0.30 and revenue of $164.9 million. Wall Street analysts maintain a "Moderate Buy" consensus for CORT, with an average price target of $88.83, and several firms recently raised their price targets.
Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data
Corcept Therapeutics (CORT) has seen a significant increase in its share price following new Korlym CATALYST and MOMENTUM trial data, which highlight its potential in treating difficult-to-control diabetes and resistant hypertension. Despite recent gains, the stock is still considered 11.9% undervalued with a fair value of $88, driven by anticipated revenue growth from Korlym's expanded use and upcoming regulatory approvals for relacorilant. The narrative for future growth relies on increased physician awareness, higher profit margins, and new revenue streams, though potential setbacks like generic pressure on Korlym or regulatory issues for relacorilant could impact this outlook.
Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data
Corcept Therapeutics (CORT) is receiving renewed attention following the presentation of new CATALYST and MOMENTUM trial data for Korlym, which demonstrates potential in treating difficult-to-control diabetes and resistant hypertension. Despite a significant recent share price rally, analysts project an $88 fair value, suggesting a small undervaluation. The future growth narrative hinges on anticipated regulatory approvals for relacorilant and an expanding market for hypercortisolism treatment, moving the company beyond single-product dependency.
Corcept Therapeutics Stock 12-Day Winning Spree: Stock Climbs 36%
Corcept Therapeutics (CORT) experienced a significant 12-day winning streak, with its stock climbing 36% and its market cap increasing by $2.1 billion to reach $7.8 billion. Despite this surge, Trefis rates CORT as "Unattractive" due to its very high valuation, moderate operating performance, and financial condition. The article highlights that these gains are already priced in, emphasizing the need for predictive signals for future investment opportunities, such as those used in the Trefis High Quality Portfolio.
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept Therapeutics (CORT) stock has surged 41.8% in the past month due to positive developments with its drug relacorilant, designed to treat Cushing’s syndrome and ovarian cancer. The company plans to resubmit its New Drug Application (NDA) for relacorilant for Cushing’s syndrome and recently received FDA approval for Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer. This approval is expected to diversify Corcept's revenue stream beyond its existing drug, Korlym, and contribute to significant revenue growth in 2026.
